Medicare Part D benzodiazepine exclusion and use of psychotropic medication by patients with new anxiety disorders

Psychiatric Services

Volumn 63, Issue 7, 2012, Pages 637-642

  Ong, Michael K ^a   Zhang, Lily ^b   Xu, Haiyong ^a   Azocar, Francisca ^c   Ettner, Susan L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c OPTUM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE;

AGED; ANXIETY DISORDER; ARTICLE; BILLING AND CLAIMS; FEMALE; GERIATRIC PATIENT; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MENTAL PATIENT; OUTPATIENT CARE; QUASI EXPERIMENTAL STUDY;

AGED; AGED, 80 AND OVER; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; BENZODIAZEPINES; COHORT STUDIES; FEMALE; HUMANS; INSURANCE COVERAGE; MALE; MANAGED CARE PROGRAMS; MEDICARE PART D; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PSYCHOTROPIC DRUGS; UNITED STATES;

EID: 84863585810     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.201100331     Document Type: Article

References (17)

1. Cutting Government Waste and Increasing Efficiency: Recommendations to the Governor. Sacramento, Calif, Bureau of State Audits, 2011
2. Fick DM, Cooper JW, Wade WE, et al: Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Archives of Internal Medicine 163:2716-2724, 2003 (Pubitemid 37517412)
3. Bambauer KZ, Sabin JE, Soumerai SB: The exclusion of benzodiazepine coverage in Medicare: simple steps for avoiding a public health crisis. Psychiatric Services 56:1143-1146, 2005 (Pubitemid 41266846)
4. Briesacher BA, Soumerai SB, Field TS, et al: Medicare Part D's exclusion of benzodiazepines and fracture risk in nursing homes. Archives of Internal Medicine 170:693-698, 2010
5. Chen H, Nwangwu A, Aparasu R, et al: The impact of Medicare Part D on psychotropic utilization and financial burden for community-based seniors. Psychiatric Services 59:1191-1197, 2008
6. Harman JS, Rollman BL, Hanusa BH, et al: Physician office visits of adults for anxiety disorders in the United States, 1985-1998. Journal of General Internal Medicine 17:165-172, 2002 (Pubitemid 34603842)
7. AHFS Drug Information 2005. Bethesda, Md, American Society of Health-System Pharmacists, 2005
8. Benzodiazepine Dependence, Toxicity, and Abuse: a Task Force Report. Washington, DC, American Psychiatric Association, 1990
9. HCUP Comorbidity Software, Version 3.2. Rockville, Md, Agency for Healthcare Research and Quality, 2007. Available at www.hcup-us.ahrq.gov/ toolssoftware/comorbidity/comorbidity.jsp
10. Ettner SL, Azocar F, Branstrom RB, et al: Association of general medical and psychiatric comorbidities with receipt of guideline-concordant care for depression. Psychiatric Services 61:1255-1259, 2010
11. Leibowitz A, Manning WG, Newhouse JP: The demand for prescription drugs as a function of cost-sharing. Social Science and Medicine 21:1063-1069, 1985 (Pubitemid 16178165)
12. Goldman DP, Joyce GF, Escarce JJ, et al: Pharmacy benefits and the use of drugs by the chronically ill. JAMA 291:2344-2350, 2004 (Pubitemid 38656301)
13. Ong M, Catalano R, Hartig T: A time-series analysis of the effect of increased copayments on the prescription of antidepressants, anxiolytics, and sedatives in Sweden from 1990 to 1999. Clinical Therapeutics 25:1262-1275, 2003 (Pubitemid 36532593)
14. Ross-Degnan D, Simoni-Wastila L, Brown JS, et al: A controlled study of the effects of state surveillance on indicators of problematic and nonproblematic benzodiazepine use in a Medicaid population. International Journal of Psychiatry in Medicine 34:103-123, 2004 (Pubitemid 39121802)
15. Simoni-Wastila L, Ross-Degnan D, Mah C, et al: A retrospective data analysis of the impact of the New York triplicate prescription program on benzodiazepine use in Medicaid patients with chronic psychiatric and neurologic disorders. Clinical Therapeutics 26:322-336, 2004 (Pubitemid 38339023)
16. Wagner AK, Soumerai SB, Zhang F, et al: Effects of state surveillance on new posthospitalization benzodiazepine use. International Journal for Quality in Health Care 15:423-431, 2003 (Pubitemid 37259379)
17. Nazareth I, Ashworth M, Hammond J, et al: Withdrawal of triazolam's product license: effect on patients 18 months later. Addiction 90:927-934, 1995